Denali Therapeutics Receives FDA Approval for AVLAYAH™
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Denali Therapeutics Inc. shares surged by 11.54% as the stock reached a 20-day high following the FDA's accelerated approval of AVLAYAH™, the first biologic treatment for Hunter syndrome in nearly 20 years.
The FDA approval of AVLAYAH™ marks a significant milestone for Denali, as it demonstrated a 91% reduction in cerebrospinal fluid heparan sulfate levels in clinical trials, indicating its potential to become a new standard of care. Additionally, Denali secured $275 million in funding from Royalty Pharma, which will support further research and development efforts for this promising treatment.
This approval not only enhances Denali's position in the rare disease market but also reflects the growing demand for effective treatments for Hunter syndrome, which has long been underserved. The company is poised to improve patient outcomes significantly with AVLAYAH™.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNLI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNLI
Wall Street analysts forecast DNLI stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.730
Low
25.00
Averages
32.78
High
40.00
Current: 24.730
Low
25.00
Averages
32.78
High
40.00
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction: Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, providing a substantial non-dilutive capital infusion that significantly strengthens its financial position.
- Product Background: The PRV was granted following the FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) in March 2026 for treating Hunter syndrome, highlighting the drug's market potential and the company's competitiveness in the rare disease sector.
- Advancing Clinical Portfolio: The capital infusion will aid Denali in advancing its broad Transport Vehicle-enabled clinical portfolio focused on lysosomal storage disorders and neurodegenerative diseases, further solidifying its position in the biopharmaceutical industry.
- Collaborations and R&D: Denali collaborates with pharmaceutical giants like Sanofi, Biogen, and Takeda to develop various candidates, and despite the discontinuation of the BIIB122 project with Biogen due to unmet expectations, the company will continue to independently advance other key studies, demonstrating resilience and promising prospects in its R&D efforts.
See More
Denali Therapeutics Sells Priority Review Voucher for $195M
- Significant Transaction Value: Denali Therapeutics announced the sale of its Priority Review Voucher for $195 million, which not only provides substantial cash flow but also enhances the company's financial flexibility in the biotech sector.
- FDA Supportive Policy: The voucher was granted by the FDA to support drug development for rare pediatric diseases, further solidifying Denali's market position in the treatment of Hunter syndrome.
- Clear Use of Funds: Denali intends to use the proceeds from this transaction to advance its pipeline projects, particularly its Alzheimer's treatment, which will aid the company's long-term growth in the neurodegenerative disease space.
- Positive Market Reaction: Following the announcement of the transaction, Denali's shares spiked in premarket trading, reflecting investor optimism regarding the company's future growth potential and enhancing its market recognition.
See More
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction Value: Denali Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million, which will significantly strengthen the company's balance sheet and support ongoing investments in its pipeline for neurodegenerative and lysosomal storage diseases.
- Strategic Alignment: The sale of the Priority Review Voucher aligns with Denali's strategy to advance innovative programs while maintaining financial flexibility to address future market challenges and opportunities.
- Strong Market Performance: Denali's stock has traded between $12.58 and $24.20 over the past year, closing at $23.49 on Wednesday with a 7.11% increase, indicating a positive market reaction to the transaction.
- Compliance Conditions: The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act, ensuring the legality and compliance of the deal.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction: Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, providing a substantial non-dilutive capital infusion that significantly strengthens its financial position.
- Product Background: The PRV was granted following the FDA's accelerated approval of Avlayah (tividenofusp alfa-eknm) in March 2026 for treating Hunter syndrome, highlighting the drug's market potential and the company's competitiveness in the rare disease sector.
- Advancing Clinical Portfolio: The capital infusion will aid Denali in advancing its broad Transport Vehicle-enabled clinical portfolio focused on lysosomal storage disorders and neurodegenerative diseases, further solidifying its position in the biopharmaceutical industry.
- Collaborations and R&D: Denali collaborates with pharmaceutical giants like Sanofi, Biogen, and Takeda to develop various candidates, and despite the discontinuation of the BIIB122 project with Biogen due to unmet expectations, the company will continue to independently advance other key studies, demonstrating resilience and promising prospects in its R&D efforts.
See More
Denali Therapeutics Sells Priority Review Voucher for $195M
- Significant Transaction Value: Denali Therapeutics announced the sale of its Priority Review Voucher for $195 million, which not only provides substantial cash flow but also enhances the company's financial flexibility in the biotech sector.
- FDA Supportive Policy: The voucher was granted by the FDA to support drug development for rare pediatric diseases, further solidifying Denali's market position in the treatment of Hunter syndrome.
- Clear Use of Funds: Denali intends to use the proceeds from this transaction to advance its pipeline projects, particularly its Alzheimer's treatment, which will aid the company's long-term growth in the neurodegenerative disease space.
- Positive Market Reaction: Following the announcement of the transaction, Denali's shares spiked in premarket trading, reflecting investor optimism regarding the company's future growth potential and enhancing its market recognition.
See More
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
- Significant Transaction Value: Denali Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million, which will significantly strengthen the company's balance sheet and support ongoing investments in its pipeline for neurodegenerative and lysosomal storage diseases.
- Strategic Alignment: The sale of the Priority Review Voucher aligns with Denali's strategy to advance innovative programs while maintaining financial flexibility to address future market challenges and opportunities.
- Strong Market Performance: Denali's stock has traded between $12.58 and $24.20 over the past year, closing at $23.49 on Wednesday with a 7.11% increase, indicating a positive market reaction to the transaction.
- Compliance Conditions: The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act, ensuring the legality and compliance of the deal.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
